NASD
| Health Care |
Biotechnology
Context Therapeutics Inc. (CNTX)
LAST (9 Apr, 9:33 AM ET)
Extended HOURS (00:00 PM ET)
MARKET CAP
VOLUME
| Open | 0.67 |
| Previous Close | 0.669 |
| Day Range | 0.65 - 0.67 |
| 52-Week Range | 0.55 - 2.72 |
| All-Time High | 10.87 |
| Avg. Volume (50-day) | 167,552.44 |
| EPS (TTM) | -0.5250 |
| Next Earnings Date | - |
| Last Earnings Date | - |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | No |
| P/E Ratio | -1.2700 |
| PEG Ratio | - |
| Price to Book | 0.63 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | - |
| Revenue per Share (TTM) | - |
| Shares Outstanding | 89.704 M |
| Share Float (%) | 52.33 M |
| % Held by Institutions | 47.51 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 0.7 (-7.83%) |
| +/- SMA(50) | 0.78 (-17.28%) |
| +/- SMA(200) | 1.6 (-59.67%) |
| 5-Day Perf. | -5.26% |
| 1-Month Perf. | -19.49% |
| 3-Month Perf. | -46.68% |
| 6-Month Perf. | -64.93% |
| YTD Perf. | -38.55% |
| 1-Year Perf. | -50.75% |
| RSI(14) | 43.71 |
| ATR(14) | 0.11 |
| ADX(14) | 14.98 |
| Beta (5Y) | - |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
Context Therapeutics Inc.
Sector: Health Care
Industry: Biotechnology
Employees: 12
Description
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
CNTX has triggered the following predefined scans:
| P&F Double Bottom Breakdown |
| P&F Spread Triple Bottom Breakdown |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
